Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease

Abstract Background To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE). Methods The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short...

Full description

Bibliographic Details
Main Authors: Yongseok Mun, Ji-Won Kwon, Joo Youn Oh
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Ophthalmology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12886-018-0910-3
id doaj-61246be1c13049cd804b25277800053f
record_format Article
spelling doaj-61246be1c13049cd804b25277800053f2020-11-24T21:23:59ZengBMCBMC Ophthalmology1471-24152018-09-011811610.1186/s12886-018-0910-3Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye diseaseYongseok Mun0Ji-Won Kwon1Joo Youn Oh2Department of Ophthalmology, Seoul National University HospitalDepartment of ophthalmology, Hanyang University College of Medicine Myongji HospitalDepartment of Ophthalmology, Seoul National University HospitalAbstract Background To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE). Methods The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short TFBUT-type DE was made based on the presence of DE symptoms, TFBUT value ≤5 s, corneoconjunctival staining score ≤ 2 (on a scale of 0 to 4), and Schirmer I value > 5 mm. Patients with systemic immunologic disorders or ocular graft-versus-host disease were excluded. Before and after instillation of 3% diquafosol ophthalmic solution six times per day for 4 weeks, subjective DE symptoms, TFBUT, corneoconjunctival staining score, and Schirmer I value were examined and compared. Also, demographic factors were compared between patients who showed improvement in each DE parameter by treatment and those who did not. Results Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment. The age of patients who showed improvement in subjective DE symptoms after treatment was significantly lower than that of patients who did not (53.4 ± 27.5 vs. 63.3 ± 13.9 years, p = 0.012). Ocular side effects developed in 3 patients (4.3%), including conjunctival chemosis (n = 1) and persistent stinging sensation (n = 2). Conclusions Diquafosol tetrasodium 3% ophthalmic solution is effective in improving subjective symptoms and tear film stability in short TFBUT-type DE patients. Trial registration The study was retrospectively registered on Clinical Research Information Service (CRiS), Republic of Korea. Trial registration number: KCT0003134. Date of registration: 2018-08-15.http://link.springer.com/article/10.1186/s12886-018-0910-3Diquafosol tetrasodium 3%Dry eye diseaseShort tear film break-up time-type dry eye
collection DOAJ
language English
format Article
sources DOAJ
author Yongseok Mun
Ji-Won Kwon
Joo Youn Oh
spellingShingle Yongseok Mun
Ji-Won Kwon
Joo Youn Oh
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
BMC Ophthalmology
Diquafosol tetrasodium 3%
Dry eye disease
Short tear film break-up time-type dry eye
author_facet Yongseok Mun
Ji-Won Kwon
Joo Youn Oh
author_sort Yongseok Mun
title Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
title_short Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
title_full Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
title_fullStr Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
title_full_unstemmed Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
title_sort therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
publisher BMC
series BMC Ophthalmology
issn 1471-2415
publishDate 2018-09-01
description Abstract Background To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE). Methods The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short TFBUT-type DE was made based on the presence of DE symptoms, TFBUT value ≤5 s, corneoconjunctival staining score ≤ 2 (on a scale of 0 to 4), and Schirmer I value > 5 mm. Patients with systemic immunologic disorders or ocular graft-versus-host disease were excluded. Before and after instillation of 3% diquafosol ophthalmic solution six times per day for 4 weeks, subjective DE symptoms, TFBUT, corneoconjunctival staining score, and Schirmer I value were examined and compared. Also, demographic factors were compared between patients who showed improvement in each DE parameter by treatment and those who did not. Results Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment. The age of patients who showed improvement in subjective DE symptoms after treatment was significantly lower than that of patients who did not (53.4 ± 27.5 vs. 63.3 ± 13.9 years, p = 0.012). Ocular side effects developed in 3 patients (4.3%), including conjunctival chemosis (n = 1) and persistent stinging sensation (n = 2). Conclusions Diquafosol tetrasodium 3% ophthalmic solution is effective in improving subjective symptoms and tear film stability in short TFBUT-type DE patients. Trial registration The study was retrospectively registered on Clinical Research Information Service (CRiS), Republic of Korea. Trial registration number: KCT0003134. Date of registration: 2018-08-15.
topic Diquafosol tetrasodium 3%
Dry eye disease
Short tear film break-up time-type dry eye
url http://link.springer.com/article/10.1186/s12886-018-0910-3
work_keys_str_mv AT yongseokmun therapeuticeffectsof3diquafosolophthalmicsolutioninpatientswithshorttearfilmbreakuptimetypedryeyedisease
AT jiwonkwon therapeuticeffectsof3diquafosolophthalmicsolutioninpatientswithshorttearfilmbreakuptimetypedryeyedisease
AT jooyounoh therapeuticeffectsof3diquafosolophthalmicsolutioninpatientswithshorttearfilmbreakuptimetypedryeyedisease
_version_ 1725990120697364480